Long-term clinical results of early-stage lung cancer patients treated with risk-adapted stereotactic body radiotherapy using LINAC or CyberKnife
Langzeitergebnisse bei Frühstadium-Lungenkrebs nach risikoadaptierter stereotaktischer Körperradiotherapie mit LINAC oder CyberKnife
Strahlentherapie und Onkologie · 2025-11 · 201 (11) · 1208-1218
DOI: 10.1007/s00066-025-02455-3 ↗Auf einen Blick
Bei 401 medizinisch inoperablen Patient:innen mit frühem Lungenkrebs waren die lokale Kontrolle und das progressionsfreie Überleben nach SBRT hoch. Schwere akute Nebenwirkungen traten nicht auf.
Fragestellung
Wie wirksam und verträglich ist SBRT mit LINAC oder CyberKnife bei medizinisch inoperablem Frühstadium-Lungenkrebs?
Methode
401 konsekutiv behandelte Patient:innen mit T1–2 N0 M0 Lungenkrebs; SBRT mit LINAC oder CyberKnife; Nachbeobachtung median 32 Monate.
Ergebnisse
Medianes OS 63 Monate (95 %-KI 51,1–74,8). Lokale Kontrolle 94 % nach 2, 90 % nach 3 und 87 % nach 4 Jahren. Keine akuten Ereignisse Grad 3 oder höher; späte Nebenwirkungen Grad 3 bei 4 Patient:innen (1 %).
Schlussfolgerung der Autor:innen
Die Autor:innen berichten hohe lokale Kontroll- und LPFS-Raten sowie günstiges PFS und OS. Eine BED10 von 132 Gy oder mehr könnte das LPFS verbessern und bei fehlenden OAR-Konflikten empfohlen werden.
Kernaussagen
- Medianes OS 63 Monate; lokale Kontrolle 94 % nach 2 Jahren
- Keine akuten Nebenwirkungen Grad 3 oder höher
- Späte Nebenwirkungen Grad 3 bei 4 Patient:innen (1 %)
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Strahlentherapie und Onkologie, online erschienen am 25.08.2025. Verfasst von Zsolt Levente Jánváry und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center of Radiotherapy, National Institute of Oncology, Budapest, Hungary. janvarylevente@gmail.com. Hauptthemen laut MEDLINE: Radiosurgery, Lung Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research, Development and Innovation Fund of the Ministry of Culture and Innovation, National Institute of Oncology.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
The aim of the study was to evaluate the clinical efficacy and side effects of stereotactic body radiotherapy (SBRT) using a gantry-based linear accelerator (LINAC) or robotic technique in a large cohort of consecutively treated medically inoperable early-stage lung cancer patients.
Methods
Between March 2015 and February 2023, 401 early-stage (T1–2 N0 M0) primary lung cancer patients were treated using either LINACs (Varian VitalBeam® and TrueBeam®; Varian, Palo Alto, CA, USA) or CyberKnife® (Accuray, Madison, WI, USA). Median age was 70 years (range 44–90). Diagnosis was based on biopsy for 37.4% of patients, while pathological confirmation was unavailable due to high risk for 62.6%. 18 F‑fluorodeoxyglucose positron-emission tomography (18-FDG-PET) was part of the pretreatment diagnostic workup in 96% ( n = 386) of the total cohort. Tumor stage distribution was T1a in 32 (8%), T1b in 179 (44.6%), T1c in 112 (27.9%), T2a in 67 (16.7%), and T2b in 11 (2.7%) patients. Applied dose schemes were identical for both LINAC and CyberKnife treatments, using risk-adapted doses of 45–60 Gy in 3 to 8 fractions, (biologically effective dose ranging from 86 to 151.2 Gy BED 10 ).
Results
At a median follow-up of 32 months (range 2–104), the crude survival rate was 58%. Median overall survival (OS) was 63 months (95% CI: 51.1–74.8) the 2‑, 3‑, and 4‑year OS rates were 79, 68, and 56%, respectively. Actuarial local control (LC) rates were 94% at 2 years, 90% at 3 years, and 87% at 4 years. Median LC was not reached. Median local progression-free survival (LPFS) and progression-free survival (PFS) rates were 49.5 months (95% CI: 42.8–56.3) and 37 months (95% CI: 31.2.–42.8), respectively. Actuarial 2‑, 3‑, and 4‑year LPFS and PFS rates were 75, 60, and 51% and 66, 51, and 42%, respectively. On multivariate analysis, BED 10 ≥ 132 Gy predicted improved LPFS, while earlier tumor stage and better ECOG performance status were associated with improved OS. No grade 3 or higher acute side effects were observed. Grade 3 late side effects occurred in 4 patients (1%), including grade 3 late pulmonary fibrosis in 3 cases and potentially treatment-related grade 3 pneumothorax in 1 patient. Rib fracture was observed in 14 cases (3%).
Conclusion
Clinical results after SBRT at a national comprehensive cancer center demonstrate high LC and LPFS rates and favorable PFS and OS, comparable to published studies. Application of a BED 10 of 132 Gy or higher shows a potential benefit in terms of LPFS and may thus be recommended in the absence of conflict with organ at risk constraints. SBRT with either LINAC or CK is proven to be a well-tolerated but still highly effective treatment for the elderly, medically inoperable early-stage lung cancer population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center of Radiotherapy, National Institute of Oncology, Budapest, Hungary. janvarylevente@gmail.com.
- National Tumor Biology Laboratory, National Institute of Oncology, Budapest, Hungary. janvarylevente@gmail.com.
- Center of Radiotherapy, National Institute of Oncology, Budapest, Hungary.
- Department of Nuclear Techniques, Institute of Nuclear Techniques, Budapest University of Technology and Economics, Budapest, Hungary.
- Department of Oncology, Oslo University Hospital, Norway, Oslo, Norway.
- Department of Radiobiology and Diagnostic Onco-Cytogenetics, Center of Radiotherapy, National Institute of Oncology, Budapest, Hungary.
ORCID-Profile: Zsolt Levente Jánváry
Förderung
- National Research, Development and Innovation Fund of the Ministry of Culture and Innovation
- National Institute of Oncology
Zitieren
APA
Jánváry, Z. L., Bajcsay, A., Stelczer, G., Kontra, G., Pócza, T., Gerdán, M., Lövey, J., Kocsis, Z. S., Ladányi, K., Pap, É., Major, T., & Polgár, C. (2025). Long-term clinical results of early-stage lung cancer patients treated with risk-adapted stereotactic body radiotherapy using LINAC or CyberKnife. Strahlentherapie und Onkologie, 201(11), 1208-1218. https://doi.org/10.1007/s00066-025-02455-3
Vancouver
Jánváry ZL, Bajcsay A, Stelczer G, Kontra G, Pócza T, Gerdán M, et al. Long-term clinical results of early-stage lung cancer patients treated with risk-adapted stereotactic body radiotherapy using LINAC or CyberKnife. Strahlentherapie und Onkologie. 2025;201(11):1208-1218. doi:10.1007/s00066-025-02455-3
BibTeX
@article{Jnvry2025,
author = {Jánváry, Zsolt Levente and Bajcsay, András and Stelczer, Gábor and Kontra, Gábor and Pócza, Tamás and Gerdán, Mercédesz and Lövey, József and Kocsis, Zsuzsa S and Ladányi, Katalin and Pap, Éva and Major, Tibor and Polgár, Csaba},
title = {Long-term clinical results of early-stage lung cancer patients treated with risk-adapted stereotactic body radiotherapy using LINAC or CyberKnife},
journal = {Strahlentherapie und Onkologie},
year = {2025},
volume = {201},
number = {11},
pages = {1208--1218},
doi = {10.1007/s00066-025-02455-3}
}
EUVIMED